Northwestern Medicine Expert and Co-Chair of the PARTNER 3 Case Review Board S. Chris Malaisrie, MD, available for Comment on Low-Risk TAVR

Newswise — The results of the clinical trial PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients will be presented at 8 a.m. Central Time on Sunday, March 17, 2019 at the ACC.19 Conference in New Orleans.

S. Chris Malaisrie, MD, a cardiac surgeon at Northwestern Memorial Hospital, associate professor of surgery (cardiac surgery) at Northwestern University Feinberg School of Medicine and co-chair of the PARTNER 3 case review board, is available to comment on the study after the embargo lifts at 8 a.m. Central Time on March 17, 2019. Dr. Malaisrie was the principal investigator of PARTNER 3 at Northwestern Medicine and a co-author on the New England Journal of Medicine article reporting the results.

Northwestern Memorial Hospital’s heart and heart surgery program is ranked in the top 10 nationally and first in Chicago, Illinois and the surrounding states by U.S. News & World Report. 

The Northwestern Medicine Bluhm Cardiovascular Institute is part of the Northwestern Medicine health system, with multiple sites of care in Chicago and the region. Northwestern Medicine is the shared strategic vision of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine.

Media looking to speak to Dr. Malaisrie should call Kara Spak, manager, Northwestern Medicine media relations at (312) 593-0596.